⌘+K

Sweden

Healthcare

Elicera Therapeutics

Equity Story

Near term

6-12 MONTHS

Elicera’s near-term equity story is driven by clinical validation, with upcoming cohort readouts from the CARMA Phase I/IIa study the key catalyst. Data from additional cohorts is expected to further inform on safety, tolerability and early efficacy signals, which we believe is critical for de-risking the iTANK platform and supporting external interest. Beyond CARMA, and with increasing focus on ELC-401 in glioblastoma, the emphasis remains on strengthening the narrative around iTANK as a modular immune-enhancing platform applicable across multiple tumour types.

Long term

6+ YEARS

The success of CARMA is critical for Elicera, since it acts as a proof of concept in humans for the whole iTANK platform, which may in the end prove to be a springboard for development in solid tumours – a potentially significant opportunity in oncology, in our view. We believe Elicera’s long-term equity story is anchored in the scalability of the iTANK platform across multiple cell-therapy modalities. Over a five-year horizon, we expect value creation to be driven by the continued clinical maturation of the CARMA programme into later-stage development, expansion into additional indications (including ELC-401 in glioblastoma) and potential partnering or out-licensing of the iTANK platform to third-party CAR T/TCR T developers.

Key risks

  • The most significant risk is related to clinical development – regulatory hurdles, potential delays and clinical trial failures

  • As an early clinical stage biotech, Elicera relies on external financing, and we believe it will require additional financing to complete CARMA as well as support operations as a whole and continue developing the pipeline

  • Partner dependence

Fair value range

Price

Fair range high value

Fair range low value

The upper end of our fair value range is derived from an SOTP analysis applying a WACC of 14%.The lower end reflects a WACC of 20%. Our SOTP includes the company’s key programmes ELC-301, ELC-401 and ELC-100, as well as the iTANK platform.

Valuation and methodology

We value Elicera Therapeutics using a probability-adjusted cash flow model, evaluating each project individually and aggregating them in an SOTP model. Our valuation includes its lead assets ELC-301, ELC-401 and ELC-100, where we see a clear path forward, discounting future cash flows with a WACC of 14–20%. We also factor in the technology value of iTANK in our scenario analysis.

Key metrics

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB